Close Menu

NEW YORK – NanoString Technologies reported after the close of the market on Thursday that its first quarter revenues shrank 4 percent year over year.

For the three months ended March 31, total revenues were $26.6 million compared with $27.7 million in the prior-year period, exceeding the average Wall Street estimate of $25.4 million.

The firm reported product and service revenue of $24.5 million for the quarter, a 15 percent year-over-year growth from $21.4 in Q1 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.